MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 74 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 1.37 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $1,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Standard LLC | 1,063,267 | $4,253,000 | 4.83% |
| 22NW, LP | 1,241,896 | $4,968,000 | 2.52% |
| Newtyn Management, LLC | 1,296,436 | $5,186,000 | 1.26% |
| Bronte Capital Management Pty Ltd. | 531,510 | $2,052,000 | 0.36% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 186,198 | $620,000 | 0.33% |
| Nantahala Capital Management | 751,943 | $3,008,000 | 0.09% |
| Sepio Capital, LP | 194,785 | $779,000 | 0.08% |
| Yakira Capital Management, Inc. | 66,934 | $268,000 | 0.08% |
| LVW Advisors, LLC | 20,000 | $80,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 61,700 | $247,000 | 0.01% |